Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
11. August 2022 16:01 ET
|
Eton Pharmaceuticals
Total Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on...
Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
02. August 2022 08:00 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)
18. Juli 2022 07:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces Sale of Hospital Products
24. Juni 2022 07:30 ET
|
Eton Pharmaceuticals
Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 millionGoing forward, Eton’s commercial portfolio will exclusively focus on products...
Eton Pharmaceuticals Reports First Quarter 2022 Financial Results
12. Mai 2022 16:02 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
03. Mai 2022 16:02 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., May 03, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer
11. April 2022 16:01 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
11. April 2022 07:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results
16. März 2022 16:02 ET
|
Eton Pharmaceuticals
Fourth Quarter 2021 Revenue of $6.1 millionFourth Quarter 2021 Net Income of $1.0 million and EPS of $0.04 DEER PARK, Ill., March 16, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq:...
Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)
14. März 2022 07:00 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine...